purchase customization

Leave This Empty:

choose chapter to purchase

table of content

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Human Microbiome Based Drugs and Diagnostics
1.2 Key Market Segments
1.2.1 Human Microbiome Based Drugs and Diagnostics Segment by Type
1.2.2 Human Microbiome Based Drugs and Diagnostics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Human Microbiome Based Drugs and Diagnostics Market Overview
2.1 Global Market Overview
2.1.1 Global Human Microbiome Based Drugs and Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Human Microbiome Based Drugs and Diagnostics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Human Microbiome Based Drugs and Diagnostics Market Competitive Landscape
3.1 Global Human Microbiome Based Drugs and Diagnostics Sales by Manufacturers (2019-2024)
3.2 Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Manufacturers (2019-2024)
3.3 Human Microbiome Based Drugs and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Human Microbiome Based Drugs and Diagnostics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Human Microbiome Based Drugs and Diagnostics Sales Sites, Area Served, Product Type
3.6 Human Microbiome Based Drugs and Diagnostics Market Competitive Situation and Trends
3.6.1 Human Microbiome Based Drugs and Diagnostics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Human Microbiome Based Drugs and Diagnostics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Human Microbiome Based Drugs and Diagnostics Industry Chain Analysis
4.1 Human Microbiome Based Drugs and Diagnostics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Human Microbiome Based Drugs and Diagnostics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Human Microbiome Based Drugs and Diagnostics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Human Microbiome Based Drugs and Diagnostics Sales Market Share by Type (2019-2024)
6.3 Global Human Microbiome Based Drugs and Diagnostics Market Size Market Share by Type (2019-2024)
6.4 Global Human Microbiome Based Drugs and Diagnostics Price by Type (2019-2024)
7 Human Microbiome Based Drugs and Diagnostics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Human Microbiome Based Drugs and Diagnostics Market Sales by Application (2019-2024)
7.3 Global Human Microbiome Based Drugs and Diagnostics Market Size (M USD) by Application (2019-2024)
7.4 Global Human Microbiome Based Drugs and Diagnostics Sales Growth Rate by Application (2019-2024)
8 Human Microbiome Based Drugs and Diagnostics Market Segmentation by Region
8.1 Global Human Microbiome Based Drugs and Diagnostics Sales by Region
8.1.1 Global Human Microbiome Based Drugs and Diagnostics Sales by Region
8.1.2 Global Human Microbiome Based Drugs and Diagnostics Sales Market Share by Region
8.2 North America
8.2.1 North America Human Microbiome Based Drugs and Diagnostics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Human Microbiome Based Drugs and Diagnostics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Human Microbiome Based Drugs and Diagnostics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Human Microbiome Based Drugs and Diagnostics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Human Microbiome Based Drugs and Diagnostics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Second Genome
9.1.1 Second Genome Human Microbiome Based Drugs and Diagnostics Basic Information
9.1.2 Second Genome Human Microbiome Based Drugs and Diagnostics Product Overview
9.1.3 Second Genome Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.1.4 Second Genome Business Overview
9.1.5 Second Genome Human Microbiome Based Drugs and Diagnostics SWOT Analysis
9.1.6 Second Genome Recent Developments
9.2 Enterome Bioscience
9.2.1 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Basic Information
9.2.2 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product Overview
9.2.3 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.2.4 Enterome Bioscience Business Overview
9.2.5 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics SWOT Analysis
9.2.6 Enterome Bioscience Recent Developments
9.3 Yakult
9.3.1 Yakult Human Microbiome Based Drugs and Diagnostics Basic Information
9.3.2 Yakult Human Microbiome Based Drugs and Diagnostics Product Overview
9.3.3 Yakult Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.3.4 Yakult Human Microbiome Based Drugs and Diagnostics SWOT Analysis
9.3.5 Yakult Business Overview
9.3.6 Yakult Recent Developments
9.4 Dowdupont
9.4.1 Dowdupont Human Microbiome Based Drugs and Diagnostics Basic Information
9.4.2 Dowdupont Human Microbiome Based Drugs and Diagnostics Product Overview
9.4.3 Dowdupont Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.4.4 Dowdupont Business Overview
9.4.5 Dowdupont Recent Developments
9.5 Vedanta BioSciences
9.5.1 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Basic Information
9.5.2 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product Overview
9.5.3 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.5.4 Vedanta BioSciences Business Overview
9.5.5 Vedanta BioSciences Recent Developments
9.6 Metabiomics Corporation
9.6.1 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Basic Information
9.6.2 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product Overview
9.6.3 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.6.4 Metabiomics Corporation Business Overview
9.6.5 Metabiomics Corporation Recent Developments
9.7 ViThera Pharmaceuticals
9.7.1 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Basic Information
9.7.2 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product Overview
9.7.3 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.7.4 ViThera Pharmaceuticals Business Overview
9.7.5 ViThera Pharmaceuticals Recent Developments
9.8 MicroBiome Therapeutics
9.8.1 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Basic Information
9.8.2 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product Overview
9.8.3 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.8.4 MicroBiome Therapeutics Business Overview
9.8.5 MicroBiome Therapeutics Recent Developments
9.9 Osel
9.9.1 Osel Human Microbiome Based Drugs and Diagnostics Basic Information
9.9.2 Osel Human Microbiome Based Drugs and Diagnostics Product Overview
9.9.3 Osel Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.9.4 Osel Business Overview
9.9.5 Osel Recent Developments
9.10 Merck
9.10.1 Merck Human Microbiome Based Drugs and Diagnostics Basic Information
9.10.2 Merck Human Microbiome Based Drugs and Diagnostics Product Overview
9.10.3 Merck Human Microbiome Based Drugs and Diagnostics Product Market Performance
9.10.4 Merck Business Overview
9.10.5 Merck Recent Developments
10 Human Microbiome Based Drugs and Diagnostics Market Forecast by Region
10.1 Global Human Microbiome Based Drugs and Diagnostics Market Size Forecast
10.2 Global Human Microbiome Based Drugs and Diagnostics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Human Microbiome Based Drugs and Diagnostics Market Size Forecast by Country
10.2.3 Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Size Forecast by Region
10.2.4 South America Human Microbiome Based Drugs and Diagnostics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Human Microbiome Based Drugs and Diagnostics by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Human Microbiome Based Drugs and Diagnostics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Human Microbiome Based Drugs and Diagnostics by Type (2025-2030)
11.1.2 Global Human Microbiome Based Drugs and Diagnostics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Human Microbiome Based Drugs and Diagnostics by Type (2025-2030)
11.2 Global Human Microbiome Based Drugs and Diagnostics Market Forecast by Application (2025-2030)
11.2.1 Global Human Microbiome Based Drugs and Diagnostics Sales (K Units) Forecast by Application
11.2.2 Global Human Microbiome Based Drugs and Diagnostics Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings